Cipla, Indian drugmaker, is all set to buy two US-based companies, InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc, for $550 million.
The deals will help the company to gain multiple products related to diabetes, anti-infectives and central nervous system disorders.